TMAM
Tokio Marine Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $603K | Buy |
4,797
+188
| +4% | +$23.6K | 0.02% | 447 |
|
|
2025
Q1 | $510K | Buy |
4,609
+426
| +10% | +$47.1K | 0.02% | 474 |
|
|
2024
Q4 | $571K | Sell |
4,183
-119
| -3% | -$16.2K | 0.02% | 447 |
|
|
2024
Q3 | $496K | Buy |
4,302
+113
| +3% | +$13K | 0.02% | 464 |
|
|
2024
Q2 | $577K | Buy |
4,189
+434
| +12% | +$59.7K | 0.03% | 394 |
|
|
2024
Q1 | $518K | Buy |
3,755
+707
| +23% | +$97.5K | 0.03% | 427 |
|
|
2023
Q4 | $402K | Buy |
3,048
+107
| +4% | +$14.1K | 0.02% | 463 |
|
|
2023
Q3 | $331K | Buy |
2,941
+344
| +13% | +$38.7K | 0.02% | 473 |
|
|
2023
Q2 | $245K | Buy |
2,597
+86
| +3% | +$8.11K | 0.02% | 527 |
|
|
2023
Q1 | $254K | Sell |
2,511
-893
| -26% | -$90.4K | 0.02% | 503 |
|
|
2022
Q4 | $407K | Buy |
3,404
+1,297
| +62% | +$155K | 0.03% | 358 |
|
|
2022
Q3 | $224K | Buy |
+2,107
| New | +$224K | 0.02% | 457 |
|